Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of SIL-8301 in Sickle Cell Disease (SCD) Patients With a Predominantly Hemolytic Phenotype

NCT07282210 is registered in ClinicalTrials.gov with Biossil Inc. as lead sponsor.

NCT NCT07282210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07282210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of SIL-8301 in Sickle Cell Disease (SCD) Patients With a Predominantly Hemolytic Phenotype
Lead sponsor
Biossil Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 13, 2026
Completion date
February 28, 2029
Enrollment
105 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anaemia, sickle cell anemia, sickle cell disease